These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23670565)

  • 21. Management of bone loss in men with prostate cancer.
    Higano CS
    J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
    Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.
    Dalla Via J; Daly RM; Owen PJ; Mundell NL; Rantalainen T; Fraser SF
    Bone; 2019 Oct; 127():367-375. PubMed ID: 31189088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.
    Lin JK; Hearn CM; Getzen E; Long Q; Lee DC; Keaveny TM; Jayadevappa R; Robinson KW; Wong YN; Maxwell KN; Narayan V; Haas NB; Takvorian SU; Bikle DD; Chiang JM; Khan AN; Rajapakse CS; Morgans AK; Parikh RB
    Eur Urol Oncol; 2024 Aug; 7(4):794-803. PubMed ID: 37926618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Lau YK
    BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.
    Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU
    Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
    Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
    Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
    Ito K; Elkin EB; Girotra M; Morris MJ
    Ann Intern Med; 2010 May; 152(10):621-9. PubMed ID: 20479027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
    Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
    Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy.
    Ziaran S; Goncalves FM; Wendl J; Trebaticky B; Breza JS
    Bratisl Lek Listy; 2009; 110(9):559-62. PubMed ID: 19827339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer.
    Jayadevappa R; Chhatre S; Malkowicz SB; Parikh RB; Guzzo T; Wein AJ
    JAMA Netw Open; 2019 Jul; 2(7):e196562. PubMed ID: 31268539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM; Ma JZ; Basler JW; Welch MD
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
    Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.